PACB (Pacific Biosciences of California) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


PACB Pacific Biosciences of California Inc PACB
53 GF Score
Price $1.60
GF Value $1.62
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Pacific Biosciences of California Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Pacific Biosciences of California's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

PACB vs CATX, LAB, KIDS: Margin of Safety % (DCF FCF Based) Comparison

For the Medical Devices subindustry, Pacific Biosciences of California's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacific Biosciences of California Margin of Safety % (DCF FCF Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's Margin of Safety % (DCF FCF Based) falls into.


PACB
53GF Score
Pacific Biosciences of California Inc PACB
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pacific Biosciences of California (PACB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued. The current stock price of $1.60 is trading 1.2% below its estimated GF Value™ of $1.62. GuruFocus considers Pacific Biosciences of California to be Fairly Valued.

Key valuation signals for PACB:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $1.62 vs. price of $1.60 (1.2% below fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Biosciences of California Business Description

Other Exchanges P09:Germany
Address 1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score

Get the complete analysis for PACB

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60
Price
$1.62
GF Value